Abstract: The present invention provides waterborne curable film-forming compositions comprising: a) an aqueous dispersion of polymeric acrylic particles, wherein the particles have a Z average particle size less than 80 nm and have reactive functional groups; wherein the particles are prepared from a monomer mixture comprising ethylenically unsaturated monomers that are polymerized in the presence of a branched polymer having an acid value of 40-200, wherein the branched polymer is prepared from ethylenically unsaturated monomers; b) a crosslinking agent having functional groups reactive with functional groups on the polymeric acrylic particles; and c) an aqueous dispersion of at least one additional polymer having hydroxyl and/or acid functional groups and having a Z average particle size greater than 100 nm. Further provided are multilayer coated substrates comprising the curable film-forming compositions and methods for forming a composite coating on a substrate using the curable film-forming compositions.

Abstract: The present invention provides waterborne curable film-forming compositions comprising: a) an aqueous dispersion of polymeric acrylic particles, wherein the particles have a Z average particle size less than 80 nm and have reactive functional groups; wherein the particles are prepared from a monomer mixture comprising ethylenically unsaturated monomers that are polymerized in the presence of a branched polymer having an acid value of 40-200, wherein the branched polymer is prepared from ethylenically unsaturated monomers; b) a crosslinking agent having functional groups reactive with functional groups on the polymeric acrylic particles; and c) an aqueous dispersion of at least one additional polymer having hydroxyl and/or acid functional groups and having a Z average particle size greater than 100 nm. Further provided are multilayer coated substrates comprising the curable film-forming compositions and methods for forming a composite coating on a substrate using the curable film-forming compositions.

Abstract: A therapeutic vector can include: a lipid particle; a CD44 antigen targeting moiety associated with the lipid particle; and a therapeutic nucleic acid associated with the lipid particle. The CD44 antigen targeting moiety can be anti-CD44 antibody and/or anti-CD44 scFv. The lipid particle can have a formula according to one of the following: DOTAP/DOPE 1:1 molar ratio; DDAB/DOPE 1:1 molar ratio; DDAB/DOPE 1:2 molar ratio; DOTAP/Chol 1:1 molar ratio; DDAB/Chol 1:1 molar ratio; DOTAP/DOPE/Chol 2:1:1 molar ratio; and DDAB/DOPE/Chol 2:1:1 molar ratio. The molar ratios can range +/?1%, 5%, 10%, or 20%. A method of inhibiting cancer development can include: providing the therapeutic vector and administering the therapeutic vector to the subject in an amount to inhibit cancer development.